Education
About Us
Working with TipRanks
Follow Us
Genfit SA (DE:XUP)
FRANKFURT:XUP
XUP Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.85 - €5.67
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$163.04M
Enterprise Value€215.61M
Total Cash (Recent Filing)€13.94M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)103.9
Beta1.25
Next Earnings
Sep 22, 2025EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding49,996,185
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.54
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.68Price Target Upside178.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Genfit News
PremiumCompany Announcements
Genfit SA Reports Profit and Strategic Advances in 2024
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.94% Public Companies and
Individual Investors
XUP FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was €2.85 and its highest was €5.67 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $163.04M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Sep 22, 2025 which is in 148 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Apr 24, 2025. The company reported -€0.235 earnings per share for the quarter, the consensus estimate of -€0.235 by €0.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is 2.2.
How many shares outstanding does Genfit SA have?
Genfit SA has 49,996,185 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€0.235 in its last earnings report, expectations of -€0.235. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in DE:XUP
---
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
---
XUP Stock 12 Month Forecast
Average Price Target
€8.68
▲(178.18% Upside)
Technical Analysis
Best Analysts Covering XUP
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
-2.48%
reiterated a buy rating 2 days ago
Copying Justine Telliez's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -2.48% per trade.
---